# A Study for Adults With Plaque Psoriasis

> **NCT01018810** · PHASE2 · TERMINATED · sponsor: **Eli Lilly and Company** · enrollment: 8 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** LY2525623 Intravenous
- **DRUG:** LY2525623 Subcutaneous
- **DRUG:** Placebo Intravenous
- **DRUG:** Placebo Subcutaneous

## Key facts

- **NCT ID:** NCT01018810
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-12
- **Primary completion:** 2010-05
- **Final completion:** 2010-08
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** The trial was terminated for several reasons, including complexities in development of LY2525623, but not because of safety concerns
- **Last updated:** 2011-07-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01018810

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01018810, "A Study for Adults With Plaque Psoriasis". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT01018810. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*